Skip to main content
SpringerLink
Log in

Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

A Correction to this article was published on 06 December 2018

This article has been updated

Abstract

The primary endpoint of this work was to evaluate the effect of safinamide on non-motor symptoms (NMS) in patients affected by idiopathic Parkinson’s disease (PD) complicated by motor fluctuations. We retrospectively collected data from 20 subjects affected by idiopathic PD in treatment with l-dopa alone or in combination with dopamine agonists, who began to be treated with safinamide due to the occurrence of motor fluctuations. Secondary endpoints included SCales for Outcomes in Parkinson’s disease (SCOPA) Motor Scale, cognitive assessment, the Hoehn and Yahr stage, Clinical Impression of Severity Index for Parkinson’s Disease, Hospital Anxiety And Depression Scale, Physical and Mental Fatigue, Parkinson’s disease Sleep Scale, Parkinson’s Disease Questionnaire-8 (PDQ-8) and EQ-5D. Each one of these scales/questionnaires was performed at baseline and T1. For efficacy analyses, continuous variables were treated with descriptive statistics, using mean and standard deviations. A non-parametric test (the Friedman test) was carried out to evaluate the statistical significance of the results observed. We found a statistically significant reduction of the total score of NMS, of 6 domains out of 9, and 13 items out of 30. A statistically significant reduction of SCOPA Motor Scale, PDQ-8, and CISI was also detected. In conclusion, our data showed a positive effect of safinamide on NMS and confirm its positive effect on motor symptomatology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Change history

  • 06 December 2018

    The original version of this article contains an error in Table 2. The Authors realized that they submitted the previous version of Table 2. The correct version of Table 2 is shown here.

References

  1. Yadav HP, Li Y (2015) The development of treatment for Parkinson’s disease. Adv Parkinsons Dis 4:59–78

    Article  CAS  Google Scholar 

  2. Schapira AH (2011) Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs 25:1061–1071

    Article  CAS  Google Scholar 

  3. Gardoni F, Bellone C (2015) Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and addiction diseases. Front Cell Neurosci 9:25

    Article  Google Scholar 

  4. Grosset DG, Macphee GJ, Nairn M, Guideline Development Group (2010) Diagnosis and pharmacological management of Parkinson’s disease: summary of SIGN guidelines. DG BMJ 340:b5614

    Article  CAS  Google Scholar 

  5. Antonini A (2009) Nonmotor symptoms in Parkinson’s disease. Eur Neurol Rev 4(2):25–27

    Article  Google Scholar 

  6. Park A, Stacy M (2009) Non-motor symptoms in Parkinson’s disease. J Neurol 256(Suppl 3):S293–S298

    Article  Google Scholar 

  7. Shoulson I, Glaubiger GA, Chase TN (1975) On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25:1144

    Article  CAS  Google Scholar 

  8. Hauser RA (2009) Levodopa: past, present. and future Eur Neurol 62:1–8

    Article  CAS  Google Scholar 

  9. Blandini F, Armentero MT (2012) New pharmacological avenues for the treatment of L-dopa-induced dyskinesias in Parkinson’s disease: targeting glutamate and adenosine receptors. Expert Opin Investig Drugs 21:153–168

    Article  CAS  Google Scholar 

  10. Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L et al (2006) Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 67(7 Suppl 2):S18–S23

    Article  CAS  Google Scholar 

  11. Onofrj M, Bonanni L, Thomas A (2008) An expert opinion on safinamide in Parkinson’s disease. Expert Opin Investig Drugs 17:1115–1125

    Article  CAS  Google Scholar 

  12. Binda C, Milczek EM, Bonivento D, Wang J, Mattevi A, Edmondson DE (2011) Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies. Curr Top Med Chem 11:2788–2796 Review

    Article  CAS  Google Scholar 

  13. Fariello RG (2007) Safinamide. Neurotherapeutics 4:110–116 Review

    Article  CAS  Google Scholar 

  14. Schapira AH (2010) Safinamide in the treatment of Parkinson’s disease. Expert Opin Pharmacother 11:2261–2268

    Article  CAS  Google Scholar 

  15. Singer C (2012) Managing the patient with newly diagnosed Parkinson disease. Cleve Clin J Med 79(Suppl 2):S3–S7

    Article  Google Scholar 

  16. Gregoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T (2013) Safinamide reduces dyskinesias and prolongs L-dopa antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord 19:508–514

    Article  Google Scholar 

  17. Deeks ED (2015) Safinamide: first global approval. Drugs 75:705–711

    Article  CAS  Google Scholar 

  18. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, Study 016 Investigators (2014) Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord 29:229–237

    Article  CAS  Google Scholar 

  19. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, the Study 018 Investigators (2014) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord 29:1273–1280

    Article  CAS  Google Scholar 

  20. Mancini F, Di Fonzo A, Lazzeri G, Borellini L, Silani V, Lacerenza M, Comi C (2018) Real life evaluation of safinamide effectiveness in Parkinson’s disease. Neurol Sci 39:733–739

    Article  Google Scholar 

  21. Bonuccelli U (2015) Effects of safinamide on motor complications and pain in advancing Parkinson’s disease – post hoc analyses of pivotal trials. European Neurological Review 10(2):176–181

    Article  Google Scholar 

  22. Cattaneo C, Barone P, Bonizzoni E, Sardina M (2017) Effects of safinamide on pain in fluctuating Parkinson’s disease patients: a post-hoc analysis. Journal of Parkinson’s Disease 7:95–101

    Article  CAS  Google Scholar 

  23. Cattaneo C, Müller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C (2017) Long-term effects of safinamide on mood fluctuations in Parkinson’s disease. Journal of Parkinson’s Disease 7(2017):629–634

    Article  CAS  Google Scholar 

  24. XADAGO® (safinamide) Summary of Product Characteristics

  25. Chaudhuri KR, Martinez-Martin P (2008) Quantitation of non-motor symptoms in Parkinson’s disease. Eur J Neurol 15:2–7

    Article  Google Scholar 

  26. Cova I, Di Battista ME, Vanacore N, Papi CP, Alampi G, Rubino A, Valente M, Meco G, Contri P, Di Pucchio A, Lacorte E, Priori A, Mariani C, Pomati S (2017) Validation of the Italian version of the nonmotor symptoms scale for Parkinson’s disease. Parkinsonism Relat Disord 34:38–42

    Article  CAS  Google Scholar 

  27. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324

    Article  Google Scholar 

  28. Prell T (2018) Structural and functional brain patterns of non-motor syndromes in Parkinson’s disease. Front Neurol 12(9):138

    Article  Google Scholar 

  29. Liguori C, Stefani A, Ruffini R, Mercuri NB, Pierantozzi M (2018) Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson’s disease patients: a validated questionnaires-controlled study. Parkinsonism Relat Disord. doi: https://doi.org/10.1016/j.parkreldis.2018.06.033

  30. Liguori C, Mercuri NB, Stefani A, Pierantozzi M (2018) Effective treatment of restless legs syndrome by safinamide in Parkinson’s disease patients. Sleep Med 41:113–114

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centro Parkinson e Disordini del Movimento ASST-SETTELAGHI, Varese, Italy

    Maria Laura Ester Bianchi & Giulio Riboldazzi

  2. Unità Semplice Riabilitazione Disordini del Movimento, Fondazione Gaetano e Piera Borghi, Brebbia, Varese, Italy

    Giulio Riboldazzi

  3. Università degli Studi dell’Insubria, Varese, Italy

    Marco Mauri & Maurizio Versino

Authors
  1. Maria Laura Ester Bianchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giulio Riboldazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Mauri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maurizio Versino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Laura Ester Bianchi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bianchi, M.L.E., Riboldazzi, G., Mauri, M. et al. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease. Neurol Sci 40, 275–279 (2019). https://doi.org/10.1007/s10072-018-3628-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-018-3628-3

Keywords

Search

Navigation